Although DexCom stock has trailed the broader market over the past year, analysts remain bullish about its prospects.

Detailed price information for Tandem Diabetes Care (TNDM-Q) from The Globe and Mail including charting and trades.

DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor ...

Dexcom welcomed the advocates to a photoshoot in Los Angeles that included Grammy-nominated artist, actor, producer and ...

The global patient monitoring devices market size is expected to reach USD 118.21 billion by 2033, registering a CAGR of 10.21% from 2025 to 2033, according to a new report by Grand View Research, Inc ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the CGM market. A strong third-quarter 2025 performance and a series of favorable coverage decisions ...

RBC Capital lowered the firm’s price target on DexCom (DXCM) to $85 from $100 but keeps an Outperform rating on the shares. The market misunderstood the conservative initial 2026 guide, which likely ...

An international study co-led by University of Calgary researchers has found new insulin delivery technology helps control ...

Protein supplements are more popular than ever, but a new report suggests that some popular powders and shakes contain unsafe levels of lead, prompting experts to recommend limiting how often you ...

BOSTON, Oct. 31, 2025 /PRNewswire/ -- Elevaris Medical Devices, a Contract Development and Manufacturing Organization for industry-leading multi-national healthcare companies, announced the ...

Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and ...